Corrigendum: When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis

Kaleen N Hayes; Ulrike Baschant; Barbara Hauser; Andrea M Burden; Elizabeth M Winter

doi:10.3389/fendo.2022.877512

Corrigendum: When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis

Front Endocrinol (Lausanne). 2022 Mar 14:13:877512. doi: 10.3389/fendo.2022.877512. eCollection 2022.

Authors

Kaleen N Hayes¹, Ulrike Baschant², Barbara Hauser^{3

4}, Andrea M Burden⁵, Elizabeth M Winter⁶

Affiliations

¹ Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, RI, United States.
² Division of Endocrinology, Diabetes and Bone Diseases, Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany.
³ Rheumatic Disease Unit, Western General Hospital, National Health Service (NHS) Lothian, Edinburgh, United Kingdom.
⁴ Rheumatology and Bone Disease Unit, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
⁵ Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology [Eidgenössische Technische Hochschule (ETH)] Zurich, Zurich, Switzerland.
⁶ Center for Bone Quality, Division of Endocrinology, Department of Internal Medicine, Leiden University Medical Center, Leiden, Netherlands.

Abstract

[This corrects the article DOI: 10.3389/fendo.2021.782118.].

Keywords: anti-resorptive treatment; bisphosphonates; bone density; bone density conservation agents; bone fractures; glucocorticoid-induced osteoporosis; glucocorticoids; teriparatide.

Publication types

Published Erratum